Back to Home
    Fundamentals

    Types of Hair Loss and Scalp Conditions: Which Ones Are Being Studied With Stem Cell Therapy?

    By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
    November 8, 20265 min read
    Types of Hair Loss and Scalp Conditions: Which Ones Are Being Studied With Stem Cell Therapy?

    What this article covers

    What This Article Covers
    "Hair loss" is not one disease — it covers at least four biologically distinct conditions, and the state of stem-cell-related research differs sharply between them. Androgenetic alopecia (pattern baldness) has the most active pipeline, with small trials of adipose-derived cells, exosomes, and engineered dermal papilla cells.
    Androgenetic Alopecia (Male and Female Pattern Hair Loss)
    This is where stem cell science is most developed, largely because the biology is tractable: pattern hair loss progressively shrinks follicles rather than destroying them outright.
    Alopecia Areata
    Alopecia areata is autoimmune — the body's own T cells attack hair follicles — so the research approach looks completely different from pattern baldness. , BMC Medicine) used "Stem Cell Educator" therapy: a patient's blood cells were briefly exposed to cord-blood-derived stem cells outside the body, then returned, with the goal of rebalancing the immune response.
    Scarring (Cicatricial) Alopecias
    Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) destroy the follicle's stem-cell-containing "bulge" region permanently through inflammation and scarring — meaning that once scarring sets in, regeneration is biologically much harder than in non-scarring hair loss. Dermatology conference reviews on this topic explicitly note the evidence gap: experts describe FFA treatment as "lacking evidence for safety and efficacy" and call for more research, pointing mainly toward earlier use of anti-inflammatory drugs like JAK inhibitors — not regenerative therapy — as the most promising near-term direction.
    Telogen Effluvium
    Telogen effluvium (diffuse shedding triggered by illness, stress, or hormonal shifts) usually resolves on its own, which makes it a hard condition to study convincingly. One 2023 retrospective study of 50 patients tested monthly microneedling sessions with adipose-derived stem cell conditioned media and reported density and thickness improvements in 70–92% of measures.

    What This Article Covers

    "Hair loss" is not one disease — it covers at least four biologically distinct conditions, and the state of stem-cell-related research differs sharply between them. Androgenetic alopecia (pattern baldness) has the most active pipeline, with small trials of adipose-derived cells, exosomes, and engineered dermal papilla cells. Alopecia areata, an autoimmune condition, has been tested with a very different "immune re-education" cell approach in a handful of patients. Scarring alopecias like lichen planopilaris and frontal fibrosing alopecia have essentially no regenerative-medicine trial data, only early lab observations about why stem cells are destroyed. And telogen effluvium has just a single small, uncontrolled study. No stem cell or exosome product is FDA-approved for any form of hair loss; everything below is investigational.

    Androgenetic Alopecia (Male and Female Pattern Hair Loss)

    This is where stem cell science is most developed, largely because the biology is tractable: pattern hair loss progressively shrinks follicles rather than destroying them outright.

    • Progenitor cell biology: A 2024–2025 study of scalp biopsies from Indian men with androgenetic alopecia found that CD34+ and Sox9+ hair follicle progenitor cells were still present in partially thinning areas but absent in fully bald areas — suggesting a window exists, before total baldness, when progenitor-targeted treatments could theoretically still work. This was a small (10-patient), observational tissue study, not a trial of any treatment.
    • Fat-derived cells (adipose-derived stem cells/SVF): Several early-phase trials (including NCT02626780 and NCT02865421) have tested stromal vascular fraction or adipose stem cell injections for pattern hair loss, generally reporting improved density in small, often uncontrolled cohorts.
    • Dermal papilla cell therapy: RepliCel's RCH-01 program injects a patient's own cultured dermal papilla cells (taken from non-balding scalp) into thinning areas — an engineered-cell approach specific to androgenetic alopecia, still in early clinical testing.
    • Exosomes: This is the most actively studied angle. A 2025 systematic review identified 11 clinical studies (298 participants, mostly androgenetic alopecia) using exosomes from sources including adipose, placental, and hair-follicle-derived mesenchymal stem cells. Two small randomized trials showed real signal — one (n=85) found hair density rose by 35 hairs/cm² with adipose-MSC exosomes plus microneedling; another (n=20) found a median gain of 9.5 hairs versus 1.5 with placebo (p=0.006). Several single-arm studies reported density gains of roughly 25–35 hairs/cm².

    Alopecia Areata

    Alopecia areata is autoimmune — the body's own T cells attack hair follicles — so the research approach looks completely different from pattern baldness. Rather than replacing follicle cells, a 2015 pilot trial (Li et al., BMC Medicine) used "Stem Cell Educator" therapy: a patient's blood cells were briefly exposed to cord-blood-derived stem cells outside the body, then returned, with the goal of rebalancing the immune response. In nine patients with severe alopecia areata, researchers reported improved hair regrowth and shifted immune cell signatures. This is genuinely interesting mechanistically, but it is a single, uncontrolled, open-label study of nine people — far too small and preliminary to draw conclusions about real-world efficacy, and a related registered trial (NCT04011748) has not reported results.

    Scarring (Cicatricial) Alopecias

    Lichen planopilaris (LPP) and frontal fibrosing alopecia (FFA) destroy the follicle's stem-cell-containing "bulge" region permanently through inflammation and scarring — meaning that once scarring sets in, regeneration is biologically much harder than in non-scarring hair loss. Dermatology conference reviews on this topic explicitly note the evidence gap: experts describe FFA treatment as "lacking evidence for safety and efficacy" and call for more research, pointing mainly toward earlier use of anti-inflammatory drugs like JAK inhibitors — not regenerative therapy — as the most promising near-term direction. There is currently no meaningful stem-cell or exosome trial data specific to LPP or FFA; the standard treatments remain anti-inflammatory and immunosuppressive drugs aimed at halting active disease before stem cells are lost.

    Telogen Effluvium

    Telogen effluvium (diffuse shedding triggered by illness, stress, or hormonal shifts) usually resolves on its own, which makes it a hard condition to study convincingly. One 2023 retrospective study of 50 patients tested monthly microneedling sessions with adipose-derived stem cell conditioned media and reported density and thickness improvements in 70–92% of measures. However, the study had no control group, combined the treatment with microneedling (a known confound), and only measured outcomes one month post-treatment — the author themselves called for randomized trials before drawing conclusions.

    Bottom Line

    Stem-cell-related research in hair loss is real but uneven: androgenetic alopecia has the broadest and most promising (if still early-stage) pipeline, especially around exosomes; alopecia areata has one intriguing but tiny immune-focused pilot study; scarring alopecias have almost no regenerative trial data and remain managed with anti-inflammatory drugs; and telogen effluvium has only preliminary, uncontrolled evidence. No stem cell or exosome therapy is FDA-approved for any hair or scalp condition, and claims of guaranteed regrowth from any clinic should be treated with skepticism regardless of subtype.

    Key Questions Answered

    Which hair-loss condition has the most stem-cell-related research?
    Androgenetic alopecia has the broadest early-stage pipeline, including adipose-derived cells, dermal papilla cells and exosomes. Small trials show signals, but the treatments remain investigational.
    Is the evidence similar for autoimmune and scarring hair loss?
    No. Alopecia areata has a tiny uncontrolled immune-focused pilot study; scarring alopecias such as LPP and FFA have no meaningful regenerative trial data, and scarring permanently destroys the follicle bulge.
    Are stem cells or exosomes approved for hair loss?
    No stem cell or exosome product is FDA-approved for any hair or scalp condition. Guaranteed-regrowth claims should be treated with skepticism regardless of the hair-loss subtype.

    Sources

    • Partial Alopecia Area Retains Bulge Hair Follicle Progenitor Cells in Indian Androgenetic Alopecia Patients, PMC, 2024, https://pmc.ncbi.nlm.nih.gov/articles/PMC12674495/
    • Li Y, et al., "Hair regrowth in alopecia areata patients following Stem Cell Educator therapy," BMC Medicine, 2015, https://pmc.ncbi.nlm.nih.gov/articles/PMC4417286/
    • Clinical Application of Stem Cell Educator Therapy in Alopecia Areata, ClinicalTrials.gov (NCT04011748), https://clinicaltrials.gov/study/NCT04011748
    • Scarring Alopecia: Cutting-Edge Approaches, European Medical Journal (dermatology congress review), https://www.emjreviews.com/dermatology/congress-review/scarring-alopecia-cutting-edge-approaches-j030123
    • Al Ameer A, et al., "Exosomes for Treating Hair Loss: A Review of Clinical Studies," Dove Medical Press, 2025, https://www.dovepress.com/article/download/106794
    • Zari S, "Efficacy of Adipocyte-Derived Stem Cells-Conditioned Media in Telogen Effluvium," Stem Cells and Cloning: Advances and Applications, 2023, https://www.dovepress.com/efficacy-of-adipocyte-derived-stem-cells-conditioned-media-in-telogen--peer-reviewed-fulltext-article-SCCAA

    Related Articles

    The Review Dispatch

    Our weekly briefing on the regenerative medicine landscape, for researchers, clinicians, and investors.

    regenmedreview

    regenmedreview is an independent reference library covering stem cell therapy and cancer immunotherapy research — compiled for researchers, clinicians, and patients exploring the field.

    The information on this site is for general educational purposes only and does not constitute medical advice. Regenerative medicine treatments discussed here may not be approved or available in all jurisdictions. Always consult a licensed physician before making treatment decisions.

    © 2026 regenmedreview. All rights reserved.Independent. Unaffiliated. Reader-supported.